A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients

被引：5

作者：

Cortellini, Alessio ^{[1
,2
]}

Ficorella, Corrado ^{[1
,2
]}

Crisci, Roberto ^{[3
]}

Divisi, Duilio ^{[3
]}

机构：

[1] Univ Aquila, San Salvatore Hosp, Med Oncol Unit, Laquila, Italy

[2] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[3] Univ Aquila, G Mazzini Hosp Teramo, Thorac Surg, Piazza Italia 1, I-64100 Teramo, Italy

来源：

JOURNAL OF THORACIC DISEASE | 2020年 / 12卷 / 10期

关键词：

T790M; NSCLC; AFATINIB;

D O I：

10.21037/jtd-20-1733

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：6107 / 6111

页数：5

共 24 条

[1]

Bruckl W, 2019, ANN ONCOL, V30, pv627

[2]

Buttitta Fiamma, 2020, Oncotarget, V11, P982, DOI 10.18632/oncotarget.27517

[3] Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) [J].

Cho, Jang Ho ;

Lim, Sung Hee ;

An, Ho Jung ;

Kim, Ki Hwan ;

Park, Keon Uk ;

Kang, Eun Joo ;

Choi, Yoon Hee ;

Ahn, Mi Sun ;

Lee, Myung Hee ;

Sun, Jong-Mu ;

Lee, Se-Hoon ;

Ahn, Jin Seok ;

Park, Keunchil ;

Ahn, Myung-Ju .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[4]

Christopoulos P, 2019, ANN ONCOL, V30

[5] Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes [J].

Cortellini, A. ;

Leonetti, A. ;

Catino, A. ;

Pizzutillo, P. ;

Ricciuti, B. ;

De Giglio, A. ;

Chiari, R. ;

Bordi, P. ;

Santini, D. ;

Giusti, R. ;

De Tursi, M. ;

Brocco, D. ;

Zoratto, F. ;

Rastelli, F. ;

Citarella, F. ;

Russano, M. ;

Filetti, M. ;

Marchetti, P. ;

Berardi, R. ;

Torniai, M. ;

Cortinovis, D. ;

Sala, E. ;

Maggioni, C. ;

Follador, A. ;

Macerelli, M. ;

Nigro, O. ;

Tuzi, A. ;

Iacono, D. ;

Migliorino, M. R. ;

Banna, G. ;

Porzio, G. ;

Cannita, K. ;

Ferrara, M. G. ;

Bria, E. ;

Galetta, D. ;

Ficorella, C. ;

Tiseo, M. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (06) :844-851

[6] Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study) [J].

Eide, Inger Johanne Zwicky ;

Helland, Aslaug ;

Ekman, Simon ;

Mellemgaard, Anders ;

Hansen, Karin Holmskov ;

Cicenas, Saulius ;

Koivunen, Jussi ;

Gronberg, Bjorn Henning ;

Brustugun, Odd Terje .

LUNG CANCER, 2020, 143 :27-35

[7]

Girard N, 2019, ANN ONCOL, V30, pv627

[8] Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study [J].

Hochmair, Maximilian J. ;

Morabito, Alessandro ;

Hao, Desiree ;

Yang, Cheng-Ta ;

Soo, Ross A. ;

Yang, James C-H ;

Gucalp, Rasim ;

Halmos, Balazs ;

Wang, Lara ;

Maerten, Angela ;

Cufer, Tanja .

FUTURE ONCOLOGY, 2019, 15 (25) :2905-2913

[9] Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib [J].

Hochmair, Maximilian J. ;

Buder, Anna ;

Schwab, Sophia ;

Burghuber, Otto C. ;

Prosch, Helmut ;

Hilbe, Wolfgang ;

Cseh, Agnieszka ;

Fritz, Richard ;

Filipits, Martin .

TARGETED ONCOLOGY, 2019, 14 (01) :75-83

[10] Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer [J].

Hong, Min Hee ;

Kim, Hye Ryun ;

Ahn, Beung-Chul ;

Heo, Su Jin ;

Kim, Jee Hung ;

Cho, Byoung Chul .

YONSEI MEDICAL JOURNAL, 2019, 60 (06) :525-534

← 1 2 3 →